Holen Sie sich die Stockscreener-App
44.39
0.57%
0.25
Handel nachbörslich:
44.20
-0.19
-0.43%
Schlusskurs vom Vortag:
$44.14
Offen:
$44.45
24-Stunden-Volumen:
12.36M
Relative Volume:
0.83
Marktkapitalisierung:
$64.33B
Einnahmen:
$20.62B
Nettoeinkommen (Verlust:
$3.56B
KGV:
18.61
EPS:
2.3847
Netto-Cashflow:
$3.48B
1W Leistung:
+3.88%
1M Leistung:
+1.09%
6M Leistung:
-30.01%
1J Leistung:
-54.60%
1-Tages-Spanne:
$43.89
$44.83
1-Wochen-Bereich:
$42.28
$44.83
52-Wochen-Spanne:
$41.38
$105.65
Boston Scientific Corp Stock (BSX) Company Profile
Firmenname
Boston Scientific Corp
Sektor
Branche
Telefon
508-683-4000
Adresse
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Compare BSX vs ABT, MDT, SYK, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
44.39 | 64.33B | 20.62B | 3.56B | 3.48B | 2.3847 |
ABT
Abbott Laboratories
|
104.89 | 181.50B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
94.75 | 121.20B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
294.66 | 113.02B | 25.27B | 3.34B | 4.57B | 8.6334 |
EW
Edwards Lifesciences Corp
|
86.60 | 49.92B | 6.30B | 1.07B | 1.09B | 1.8406 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-10-07 | Eingeleitet | Barclays | Equal Weight |
| 2026-09-17 | Herabstufung | Citigroup | Buy → Neutral |
| 2026-07-31 | Herabstufung | Argus | Buy → Hold |
| 2026-05-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2026-05-28 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2026-03-30 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-10-03 | Herabstufung | Erste Group | Buy → Hold |
| 2025-09-08 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-06-16 | Eingeleitet | Leerink Partners | Outperform |
| 2025-04-16 | Hochstufung | Needham | Hold → Buy |
| 2025-01-10 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-10-18 | Herabstufung | Needham | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-02-01 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-06-30 | Eingeleitet | CL King | Buy |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-12-22 | Eingeleitet | Mizuho | Neutral |
| 2022-12-20 | Fortgesetzt | Citigroup | Buy |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-05-27 | Hochstufung | Needham | Hold → Buy |
| 2022-04-13 | Fortgesetzt | Truist | Buy |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-05-26 | Herabstufung | Needham | Buy → Hold |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-17 | Eingeleitet | Truist | Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-04-22 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-01 | Hochstufung | Goldman | Neutral → Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Buy |
| 2019-12-30 | Bestätigt | Cowen | Outperform |
| 2019-12-19 | Herabstufung | Needham | Strong Buy → Buy |
| 2019-09-05 | Fortgesetzt | JP Morgan | Overweight |
| 2019-09-03 | Fortgesetzt | Barclays | Overweight |
| 2019-05-13 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-11-28 | Eingeleitet | UBS | Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-10-02 | Bestätigt | Morgan Stanley | Overweight |
| 2018-09-07 | Bestätigt | Needham | Strong Buy |
| 2018-09-04 | Hochstufung | Jefferies | Hold → Buy |
| 2018-07-06 | Bestätigt | Needham | Strong Buy |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-04-26 | Bestätigt | Needham | Strong Buy |
Alle ansehen
Boston Scientific Corp Aktie (BSX) Neueste Nachrichten
Boston Scientific (BSX) Rises Higher Than Market: Key Facts - Zacks Investment Research
Why Did J&J Stock Fall After Q3 Earnings Despite Raised Guidance? - Zacks Investment Research
Why Boston Scientific (BSX) Outpaced the Stock Market Today - Zacks Investment Research
China Adult Feeding Tubes and Formula Market Outlook to 2033Revenue, Volume, Pricing, and Company Share | Forecast Data Reveals Market Entry and Expansion Opportunities - GlobeNewswire Inc.
Boston Scientific (BSX) Advances While Market Declines: Some Information for Investors - Zacks Investment Research
Boston Scientific Corporation (BSX) is Attracting Investor Attention: Here is What You Should Know - Zacks Investment Research
Boston Scientific (BSX) Names Joseph Fitzgerald COO, Restructures Segments Starting 2027 - GuruFocus
Form 8-K BOSTON SCIENTIFIC CORP For: Oct 01 - StreetInsider
Boston Scientific names Fitzgerald COO, creates three segments By Investing.com - Investing.com Canada
Three business units will be created at Boston Scientific in January. - Stock Titan
Stryker (SYK) vs Boston Scientific (BSX): Which is a Better Stock to Buy? - Yahoo Finance
Global Bioelectronic Medicine Market Anticipates Impressive Growth Trajectory of ~10% by 2034 | DelveInsight - GlobeNewswire Inc.
Can J&J's MedTech Business Rebound in Q3 After Q2 Slowdown? - Zacks Investment Research
Bernstein cuts Boston Scientific stock price target on device competition - Investing.com
Bernstein Keeps Their Buy Rating on Boston Scientific (BSX) - The Globe and Mail
Boston Scientific (BSX) Receives a Buy from RBC Capital - The Globe and Mail
Bernstein Keeps Their Buy Rating on Boston Scientific (BSX) - The Globe and Mail
Boston Scientific Corporation (BSX) Stock Forecasts - Yahoo Finance
Boston Scientific (BSX) Stock Sinks As Market Gains: What You Should Know - Zacks Investment Research
Boston Scientific Corp. stock underperforms Friday when compared to competitors - MarketWatch
Boston Scientific Corp. stock underperforms Friday when compared to competitors - MarketWatch
If You Invested $1000 In Boston Scientific Stock 15 Years Ago, You Would Have This Much Today - Benzinga
Boston Scientific stock hits 52-week low at 42.14 USD - Investing.com
Can ISRG Offset China Weakness With Expansion in India and Japan? - Zacks Investment Research
Boston Scientific Corporation (BSX) Stock forecasts - Yahoo Finance Australia
Elutia receives $8 million escrow from Boston Scientific sale - Investing.com
Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029 - marketscreener.com
Boston Scientific's MedSurg Diversification Bolsters Growth Prospects - Zacks Investment Research
Boston Scientific stock absorbs a USD 20.00 target cut - AD HOC NEWS
Boston Scientific stock ahead of the Xetra open as newsroom lists cybersecurity update - AD HOC NEWS
Is Boston Scientific (NYSE:BSX) Facing a Real Market Test? - Kalkine Media
Boston Scientific (BSX) Secures $135.7M Cardiovascular Contract with U.S. Military - GuruFocus
Could Boston Scientific’s $300 Million Cyber Hit Be Mostly a 2026 Problem? - Yahoo Finance
Why Oppenheimer Cut Boston Scientific’s Price Target by $20 Despite Keeping its Outperform Rating - Yahoo Finance
FDA Flags Boston Scientific Catheter Recall - Benzinga
FDA Flags Boston Scientific Catheter Recall - Benzinga
Boston Scientific (BSX) Faces A Recall, Is The 28% Undervaluation Still Compelling? - Yahoo Finance
FDA Finally Approves Watchman Device from Boston Scientific - Medical Product Outsourcing
BSX.GE Bond Profile: Coupon and Redemption - TradingView
Boston Scientific Corp. stock underperforms Friday when compared to competitors - MarketWatch
Mexico Cardiac Rhythm Management Devices Market Outlook to 2036 Provides Revenue, Volume, Pricing and Competitive Insig - GlobeNewswire Inc.
Boston Scientific (BSX) Stock Moves 2.74%: What You Should Know - Yahoo Finance
Will Boston Scientific's Upcoming Launches Fuel the Next Growth Phase? - Zacks Investment Research
Citi downgrades Boston Scientific on uncertain recovery path - Yahoo Finance
Boston Scientific: A Great Company At A Deeply Discounted Price (Rating Upgrade) - Seeking Alpha
Why Did BSX Cut FY26 Guidance? CEO Details Three Unanticipated Factors At Bernstein Conference - Stocktwits
Boston Scientific stock falls as cyberattack clouds 2026 outlook - ad-hoc-news.de
Is Boston Scientific (BSX) a Buy as Wall Street Analysts Look Optimistic? - Yahoo Finance
Boston Scientific fully restores operations after cyberattack - Yahoo Finance
What Is Moving the Story Around Boston Scientific (BSX)? - Kalkine Media
Finanzdaten der Boston Scientific Corp-Aktie (BSX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Boston Scientific Corp-Aktie (BSX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Morano Susan E | Director |
Aug 25 '26 |
Buy |
49.22 |
2,040 |
100,408 |
13,784 |
| Habiger David C | Director |
Aug 05 '26 |
Buy |
47.59 |
2,100 |
99,937 |
17,160 |
| Habiger David C | Director |
Aug 04 '26 |
Buy |
48.59 |
140 |
6,802 |
15,060 |
| Mahoney Michael F | Chairman, President & CEO |
Aug 03 '26 |
Buy |
48.33 |
186,240 |
9,001,408 |
1,590,024 |
| Habiger David C | Director |
Aug 03 '26 |
Buy |
48.07 |
1,042 |
50,084 |
14,920 |
| LUDWIG EDWARD J | Director |
Jul 31 '26 |
Buy |
45.48 |
5,000 |
227,400 |
30,359 |
| Monson Jonathan | EVP and CFO |
Jul 01 '26 |
Option Exercise |
0.00 |
2,087 |
0 |
40,073 |
| Pegus Cheryl | Director |
May 20 '26 |
Buy |
56.49 |
1,770 |
99,987 |
1,770 |
| LUDWIG EDWARD J | Director |
May 20 '26 |
Buy |
56.68 |
3,580 |
202,914 |
25,359 |
| Habiger David C | Director |
May 20 '26 |
Buy |
55.92 |
2,250 |
125,819 |
13,878 |
1.70%
0.98%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):